Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Recruiting

Interested in participating?

Key information

Conditions

ITP - Immune Thrombocytopenia Autoimmune Diseases Blood Coagulation Disorders Blood Platelet Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hemorrhagic Disorders Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Purpura Purpura, Thrombocytopenic Purpura, Thrombocytopenic, Idiopathic Signs and Symptoms Skin Manifestations Thrombocytopenia Thrombotic Microangiopathies

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sohag university hospital

Sohag, Egypt

Location status: Recruiting

Location contact

Magdy M Amin, Professor

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver

Exclusion criteria

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Treatment and study plan

eltrombopag

Drug

ITP patients will receive Eltrombopag and evulate occurance of liver disordres .

Primary outcomes

•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Time frame: 3-6 months after receiving eltombopag

the incidence and severity of liver dysfunction in ITP patients

Study contacts

Contact information is provided by the study sponsor or research team.

Peter A Alfy, Resident

CONTACT

[email protected]

01274069691

Usama M Abdelaal, Professor

CONTACT

01065962094

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jul 30, 2025
Registry last updated: Jul 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting